NDA 203629 · Fresenius Kabi USA
Neostigmine Methylsulfate
Neostigmine Methylsulfate · Intravenous
Last checked: Nov 20, 2026Latest source record: Feb 4, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Jan 8, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
231
33 Phase 3, 11 recruiting
FAERS reports
365
331 serious, 53 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 15, 2024.
Neostigmine Methylsulfate Injection, a cholinesterase inhibitor, is indicated for reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after surgery. Neostigmine Methylsulfate, a cholinesterase inhibitor, is indicated for reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after surgery ( 1 ).
Mechanism: Neostigmine methylsulfate is a competitive cholinesterase inhibitor. By reducing the breakdown of acetylcholine, neostigmine methylsulfate induces an increase in acetylcholine in the synaptic cleft which competes for the same binding site as nondepolarizing neuromuscular blocking agents, and reverses the neuromuscular blockade.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 8, 2015 Original approval · Type 3 - New Dosage Form LabelSummary ReviewLetter
3 products under this application
- NEOSTIGMINE METHYLSULFATE · NEOSTIGMINE METHYLSULFATE 3MG/3ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- NEOSTIGMINE METHYLSULFATE · NEOSTIGMINE METHYLSULFATE 5MG/10ML (0.5MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- NEOSTIGMINE METHYLSULFATE · NEOSTIGMINE METHYLSULFATE 10MG/10ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Neostigmine Methylsulfate" as an intervention, any sponsor and status, largest first.
- Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01422304 · 1,198 participants · Start Oct 12, 2011 · Primary completion Sep 26, 2012
Drug: Sugammadex; neostigmine and glycopyrrolate or atropine and 2 more · For: Neuromuscular Blockade; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee and 2 more
- Effect of Intrathecal Neostigmine on Post-dural Puncture Headache.Pivotal-lookingCompleted
Alexandria UniversityAcademic, hospital or other
NCT05289323 · 722 participants · Start Apr 25, 2022 · Primary completion Jul 25, 2023
Drug: Neostigmine Methylsulfate; Dextrose 5%/Nacl 0.9% Inj · For: Post-Dural Puncture Headache
Sites: Alexandria, Egypt
- Neuromuscular Blocking Agents on Gastrointestinal Function Following Colorectal SurgeryPivotal-lookingNot yet recruiting
Xijing HospitalAcademic, hospital or other
NCT07271875 · 560 participants (planned) · Start Jan 1, 2026 · Primary completion Nov 30, 2027
Drug: Neostigmine + Atropine; Sugammadex · For: Postoperative Gastrointestinal Dysfunction (POGD); Postoperative Ileus; Colorectal Surgery
- Modern Myorelaxation Procedure and Reversal of Neuromuscular Blockade With General Anesthesia for Caesarean SectionPivotal-lookingCompleted
Brno University HospitalAcademic, hospital or other
NCT01718236 · 500 participants · Start Sep 2012 · Primary completion Jan 2015
Drug: Rocuronium + sugammadex; Succinylcholine + Neostigmine · For: Caesarean Section; Pregnancy
Sites: Olomouc, Czechia; Brno, Czechia
- Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney DiseasePivotal-lookingRecruiting
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT07203287 · 490 participants (planned) · Start Aug 26, 2025 · Primary completion Dec 31, 2026
Drug: Rocuronium; Cisatracurium and 2 more · For: Post Operative Pulmonary Complications; Neuromuscular Blockade; General Anesthesia
Sites: Galveston, Texas
- Emergence AgitationPivotal-lookingActive, not recruiting
Ain Shams UniversityAcademic, hospital or other
NCT07253428 · 486 participants (planned) · Start Oct 30, 2025 · Primary completion Dec 31, 2025
Drug: Neostigmine + Atropine; Sugamadex · For: Emergence Agitation; Nasal Surgery
Sites: Ha'il, Saudi Arabia
- Influence of Neostigmine vs. Sugammadex on PORC and PPCs by UltrasonographyPivotal-lookingStatus unknown
Peking Union Medical College HospitalAcademic, hospital or other
NCT05040490 · 414 participants (planned) · Start Aug 31, 2021 · Primary completion Jul 2022
Drug: sugammadex as reversal drugs · For: Postoperative Pulmonary Complications
- Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic LavagePivotal-lookingCompleted
US Department of Veterans AffairsFederal agency
NCT00745095 · 360 participants · Start Mar 2009 · Primary completion Mar 2013
Drug: Neostigmine · For: Spinal Cord Injury
Sites: The Bronx, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective34
- abdominal distension25
- nausea23
- hypotension22
- respiratory failure20
- abdominal pain19
- white blood cell count increased18
- cardiac arrest16
- pyrexia16
- bradycardia15
- generalised tonic-clonic seizure15
- subileus15
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 5 |
| 2006 | 6 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 6 |
| 2010 | 5 |
| 2011 | 3 |
| 2012 | 16 |
| 2013 | 9 |
| 2014 | 16 |
| 2015 | 11 |
| 2016 | 23 |
| 2017 | 19 |
| 2018 | 25 |
| 2019 | 26 |
| 2020 | 20 |
| 2021 | 20 |
| 2022 | 29 |
| 2023 | 34 |
| 2024 | 45 |
| 2025 | 29 |
| 2026 | 11 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Jan 12, 2026
Neostigmine Methylsulfate, Injection, .5 mg/1 mL (NDC 63323-413-10). Discontinuation of the manufacture of the drug
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cerebrospinal fluid pharmacokinetics and pharmacodynamics of intrathecal neostigmine methylsulfate in humans.
Shafer SL, Eisenach JC, Hood DD, et al. · Anesthesiology 1998 · Clinical Trial, Research Support, U.S. Gov't, P.H.S.
- Phase I safety assessment of intrathecal neostigmine methylsulfate in humans.
Hood DD, Eisenach JC, Tuttle R · Anesthesiology 1995 · Clinical Trial, Clinical Trial, Phase I
- Influence of reversal of neuromuscular blockade with sugammadex or neostigmine on postoperative quality of recovery following a single bolus dose of rocuronium: A prospective, randomized, double-blinded, controlled study.
Kim NY, Koh JC, Lee KY, et al. · J Clin Anesth 2019 · Comparative Study, Randomized Controlled Trial
- Neostigmine Administered With MoviPrep Improves Bowel Preparation for Elective Colonoscopy in Patients With Spinal Cord Injury: A Randomized Study.
Korsten MA, Spungen AM, Radulovic M, et al. · J Clin Gastroenterol 2015 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- The effect of epidural neostigmine combined with ropivacaine and sufentanil on neuraxial analgesia during labor.
Roelants F, Rizzo M, Lavand'homme P · Anesth Analg 2003 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Fresenius Kabi USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.